Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY D CIZENSKI

Allopathic & Osteopathic Physicians Dermatology

NPI
1821437104
CMS profile
1390399
Location
EAST SYRACUSE, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$73,752.96

181 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY D CIZENSKI

NPI 1821437104 · CMS profile ID 1390399

Allopathic & Osteopathic Physicians / Dermatology

EAST SYRACUSE, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821437104?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY D CIZENSKI, NPI 1821437104, CMS profile ID 1390399. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821437104?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JEFFREY D CIZENSKI, NPI 1821437104, CMS profile ID 1390399. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821437104?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JEFFREY D CIZENSKI, NPI 1821437104, CMS profile ID 1390399, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1821437104?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

181 matching records · $73,752.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 181 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 181.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Galderma Laboratories, L.P. $600.0009/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855268771 CMS
AbbVie Inc. $17.8709/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794262211 CMS
Lilly USA, LLC $1,800.0009/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818554033 CMS
Lilly USA, LLC $1,125.0009/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819159483 CMS
UCB, Inc. $18.8609/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807407241 CMS
AbbVie Inc. $14.9809/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794262209 CMS
Amgen Inc. $67.2009/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826357929 CMS
Amgen Inc. $3,000.0009/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826357933 CMS
Amgen Inc. $500.0009/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826357937 CMS
Amgen Inc. $3.9009/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826357941 CMS
Lilly USA, LLC $52.4809/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819142465 CMS
GENZYME CORPORATION $1,362.0009/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843694821 CMS
AbbVie Inc. $25.9609/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794262207 CMS
Lilly USA, LLC $7.2809/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818562715 CMS
LEO Pharma Inc. $17.4209/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842161843 CMS
Amgen Inc. $125.0008/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826357945 CMS
Lilly USA, LLC $1,800.0008/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818554031 CMS
Lilly USA, LLC $675.0008/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818562929 CMS
Lilly USA, LLC $450.0008/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818576487 CMS
AbbVie Inc. $1.7408/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794262203 CMS
AbbVie Inc. $18.8108/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794262205 CMS
Lilly USA, LLC $65.9608/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818562923 CMS
Novartis Pharmaceuticals Corporation $24.0008/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812639779 CMS
GENZYME CORPORATION $24.7308/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843694777 CMS
Galderma Laboratories, L.P. $8.0508/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855268769 CMS
Janssen Biotech, Inc. $10.7008/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788721897 CMS
Galderma Laboratories, L.P. $1,950.0008/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855268767 CMS
UCB, Inc. $15.4208/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807390773 CMS
Lilly USA, LLC $25.1607/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818563711 CMS
Galderma Laboratories, L.P. $81.5907/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855268765 CMS
Regeneron Healthcare Solutions, Inc. $15.8707/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809567607 CMS
VYNE Pharmaceuticals Inc. $7.2107/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830825353 CMS
Janssen Biotech, Inc. $13.1107/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788721913 CMS
Janssen Biotech, Inc. $1.8807/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788721915 CMS
Amgen Inc. $2,500.0007/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826357925 CMS
Novartis Pharmaceuticals Corporation $14.4607/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812639777 CMS
Biofrontera Inc. $16.5607/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803505473 CMS
GENZYME CORPORATION $17.2407/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843694783 CMS
Amgen Inc. $18.8807/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826357921 CMS
UCB, Inc. $14.2107/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807368473 CMS
AbbVie Inc. $12.4507/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794262201 CMS
SANOFI-AVENTIS U.S. LLC $56.3907/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843694753 CMS
ORGANOGENESIS INC. $19.5407/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835462331 CMS
Incyte Corporation $64.2707/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835573135 CMS
Lilly USA, LLC $900.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818563709 CMS
Regeneron Healthcare Solutions, Inc. $124.9906/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809567603 CMS
Lilly USA, LLC $900.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819159479 CMS
PFIZER INC. $30.9106/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832856867 CMS
LEO Pharma Inc. $13.5006/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842161827 CMS
Lilly USA, LLC $900.0006/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818554029 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $564.73 30
PY2020 $38,672.21 101
PY2021 $73,752.96 181
PY2022 $192,918.09 384
PY2023 $247,917.15 396
PY2024 $200,464.41 329
PY2025 $276,554.93 408

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $208,285.68 51
PY2024 Principal investigator $247,137.23 48
PY2023 Principal investigator $167,095.57 19
PY2022 Principal investigator $48,341.00 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,917.00 12/19/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531683
Principal investigator 1 Incyte Corporation $320.40 12/11/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531689
Principal investigator 1 ABBVIE INC. $18,722.08 12/04/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY PLLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202528874
Principal investigator 1 Incyte Corporation $5,472.40 12/04/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531693
Principal investigator 1 Incyte Corporation $7,721.70 12/04/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531696
Principal investigator 1 Incyte Corporation $1,800.00 11/25/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531679
Principal investigator 1 Incyte Corporation $1,479.60 11/07/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531675
Principal investigator 1 PFIZER INC. $1,894.97 11/04/2025 Non-covered Recipient Entity
Empire Dermatology PLLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228729760
Principal investigator 1 Janssen Research & Development, LLC $10,290.00 10/23/2025 Non-covered Recipient Entity
Empire Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175247398
Principal investigator 1 Incyte Corporation $2,237.40 10/16/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531670
Principal investigator 1 Incyte Corporation $1,917.00 10/09/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531667
Principal investigator 1 Biofrontera Inc. $14,317.31 09/29/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY PLLC
EFFICACY OF RED-LIGHT PHOTODYNAMIC THERAPY WITH 10% ALA GEL FOR THE TREATMENT OF KERATOACANTHOMA No dispute reported 06/30/2026 1208907612
Principal investigator 1 Incyte Corporation $1,159.20 09/23/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531652
Principal investigator 1 Incyte Corporation $320.40 09/18/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531655
Principal investigator 1 Incyte Corporation $2,557.80 09/04/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531648
Principal investigator 1 Incyte Corporation $1,089.00 08/26/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531639
Principal investigator 1 Incyte Corporation $1,133.10 08/21/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531643
Principal investigator 1 Janssen Research & Development, LLC $19,110.00 08/19/2025 Non-covered Recipient Entity
Empire Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175247382
Principal investigator 1 PFIZER INC. $1,378.61 08/05/2025 Non-covered Recipient Entity
Empire Dermatology PLLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228720153
Principal investigator 1 Incyte Corporation $1,159.20 07/22/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531636
Principal investigator 1 Incyte Corporation $320.40 07/17/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531631
Principal investigator 1 PFIZER INC. $51.48 07/11/2025 Non-covered Recipient Entity
Empire Dermatology PLLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228764169
Principal investigator 1 Incyte Corporation $129.49 07/10/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240531659
Principal investigator 1 Incyte Corporation $4,338.00 07/10/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240531663
Principal investigator 1 Incyte Corporation $1,917.00 07/04/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531627
Principal investigator 1 PFIZER INC. $5,621.30 06/26/2025 Non-covered Recipient Entity
Empire Dermatology PLLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228775874
Principal investigator 1 Incyte Corporation $3,007.80 06/24/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531608
Principal investigator 1 Incyte Corporation $1,159.20 06/19/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531614
Principal investigator 1 Janssen Research & Development, LLC $11,025.00 06/19/2025 Non-covered Recipient Entity
Empire Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175247509
Principal investigator 1 Incyte Corporation $1,089.00 06/05/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531618
Principal investigator 1 PFIZER INC. $2,746.48 05/30/2025 Non-covered Recipient Entity
Empire Dermatology PLLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228764192
Principal investigator 1 PFIZER INC. $12,803.68 05/29/2025 Non-covered Recipient Entity
Empire Dermatology PLLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228772663
Principal investigator 1 Incyte Corporation $2,548.80 05/28/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531600
Principal investigator 1 Incyte Corporation $1,089.00 05/22/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531596
Principal investigator 1 Incyte Corporation $1,159.20 05/15/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531604
Principal investigator 1 PFIZER INC. $3,277.42 05/06/2025 Non-covered Recipient Entity
Empire Dermatology PLLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228764533
Principal investigator 1 Incyte Corporation $58.00 05/01/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531592
Principal investigator 1 Incyte Corporation $7,839.90 04/28/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531577
Principal investigator 1 Incyte Corporation $1,089.00 04/23/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531581
Principal investigator 1 Janssen Research & Development, LLC $735.00 04/23/2025 Non-covered Recipient Entity
Empire Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175247389
Principal investigator 1 Incyte Corporation $1,274.40 04/15/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531589
Principal investigator 1 PFIZER INC. $241.45 04/09/2025 Non-covered Recipient Entity
Empire Dermatology
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228770776
Principal investigator 1 PFIZER INC. $1,877.03 04/08/2025 Non-covered Recipient Entity
Empire Dermatology PLLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228779062
Principal investigator 1 Incyte Corporation $5,711.02 04/03/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240531623
Principal investigator 1 Incyte Corporation $5,369.40 04/01/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531585
Principal investigator 1 PFIZER INC. $1,735.43 03/22/2025 Non-covered Recipient Entity
Empire Dermatology PLLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228789536
Principal investigator 1 Incyte Corporation $6,535.80 03/19/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531574
Principal investigator 1 PFIZER INC. $7,459.23 02/26/2025 Non-covered Recipient Entity
Empire Dermatology PLLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228723490
Principal investigator 1 Janssen Research & Development, LLC $16,170.00 01/21/2025 Non-covered Recipient Entity
Empire Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175247502
Principal investigator 1 Incyte Corporation $1,992.60 01/17/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531704
Principal investigator 1 Incyte Corporation $1,917.00 01/07/2025 Non-covered Recipient Entity
EMPIRE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531700